drugset / Trial / NCT00035243

EPO906 Therapy in Patients With Advanced Kidney Cancer

NCT00035243

Phase 2 Completed 53 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.

Timeline

Start
2002-04
Primary completion
2003-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Patupilone Small molecule 2.5 mg/m2 Intravenous

Indications